Company / Cash & Equivalents
Scholar Rock Holding Corp Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$323.5M
FY2025
5-year range
$101.9M / $323.5M
FY2021-FY2025
Trend
+81.9%
vs FY2024
Sector context
#59 of 207
Health Care
What the data says
At $324M, Scholar Rock Holding Corp's cash & equivalents ranks #59 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 9 years, ranging from $36M in FY2019 to $324M in FY2025.
Based on SEC 10-K filings.
$324M in FY2025 with a 5-year CAGR of +15.1%.
Improved from $102M to $324M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +46.3%
- 5-Year CAGR
- +15.1%
- 10-Year CAGR
- -
Sector benchmark
#59 of 207 in Health CareTop 29% of 207This company $323.5M Sector average $669.5M
▼
-51.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 81.9% year-over-year.
- Ranks #59 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $323.5M | +81.9% |
| FY2024 | $177.9M | +74.6% |
| FY2023 | $101.9M | -1.4% |
| FY2022 | $103.3M | -51.5% |
| FY2021 | $212.8M | +32.7% |
| FY2020 | $160.4M | +341.7% |
| FY2019 | $36.3M | -68.4% |
| FY2018 | $115.1M | +103.8% |
| FY2017 | $56.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026